Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of combined recombinant human growth hormone and IGF-1 in paediatric Crohn's disease
2010-022215-19Phase 2Terminated
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Jun 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of somatropin and mecasermin in Crohn's disease and Growth disorder (2 arms), sponsored by NHS Greater Glasgow and Clyde. Primary endpoint: Safety and tolerability of dual IMP administration compared to individual IMP. Started Jun 2011; status: terminated.
02
Drugs
somatropinmecasermin
03
Conditions
Crohn's diseaseGrowth disorder
Beyond the preview
Go deeper on 2010-022215-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022215-19.